about
Development of a spherical (125)i-brachytherapy seed for its application in the treatment of eye and prostate cancer.Development of a new design (125)I-brachytherapy seed for its application in the treatment of eye and prostate cancer.A facile, viable approach toward the preparation of 32p patches for the treatment of skin cancer.Nafion-zirconium phosphate composite membrane: a new approach to prepare (32)P patches for superficial brachytherapy applications.Indigenous (125)I brachytherapy source for the management of intraocular melanomas in India.Peptide receptor radionuclide therapy: an overview.Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.Episcleral plaque brachytherapy using 'BARC I-125 Ocu-Prosta seeds' in the treatment of intraocular tumors: a single-institution experience in IndiaPreparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximabBrachytherapy of intra ocular tumors using 'BARC I-125 Ocu-Prosta seeds': an Indian experience.Availability of yttrium-90 from strontium-90: a nuclear medicine perspective.99Mo/(99m)Tc separation: an assessment of technology options.Role of nanoporous materials in radiochemical separations for biomedical applications.Palliative care of bone pain due to skeletal metastases: Exploring newer avenues using neutron activated (45)Ca.Radiochemistry, pre-clinical studies and first clinical investigation of 90Y-labeled hydroxyapatite (HA) particles prepared utilizing 90Y produced by (n,γ) route.Sustained availability of 99mTc: possible paths forward.Measurement of residence time distribution of liquid phase in an industrial-scale continuous pulp digester using radiotracer technique.Toward realization of 'mix-and-use' approach in ⁶⁸Ga radiopharmacy: preparation, evaluation and preliminary clinical utilization of ⁶⁸Ga-labeled NODAGA-coupled RGD peptide derivative.Radiolabeling and Preliminary Evaluation of Ga-68 Labeled NODAGA-Ubiquicidin Fragments for Prospective Infection Imaging.Fabrication of cesium-137 brachytherapy sources using vitrification technology.A novel electrochemical technique for the production of clinical grade 99mTc using (n, gamma)99Mo.Usefulness of nano-zirconia for purification and concentration of ¹²⁵I solution for medical applications.The practicality of nanoceria-PAN-based (68)Ge/(68)Ga generator toward preparation of (68)Ga-labeled cyclic RGD dimer as a potential PET radiotracer for tumor imaging.Recovery and purification of 4.66 TBq(126Ci) of 137Cs from a 20-year-old spent sealed source.Synthesis and biological evaluation of 90Y-labeled porphyrin-DOTA conjugate: a potential molecule for targeted tumor therapy.Polymer embedded nanocrystalline titania sorbent for 99Mo-99mTc generator.Development of technology for the large-scale preparation of 60Co polymer film source.Development of an electrochemical 90 Sr-90 Y generator for separation of 90 Y suitable for targeted therapy.Detailed evaluation on the effect of metal ion impurities on complexation of generator eluted 68Ga with different bifunctional chelators.(90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation.Diversification of 99Mo/99mTc separation: non–fission reactor production of 99Mo as a strategy for enhancing 99mTc availability.Preparation, evaluation, and first clinical use of 177Lu-labeled hydroxyapatite (HA) particles in the treatment of rheumatoid arthritis: utility of cold kits for convenient dose formulation at hospital radiopharmacy.Detailed evaluation of different (68)Ge/(68)Ga generators: an attempt toward achieving efficient (68)Ga radiopharmacy.Reactor production and electrochemical purification of (169)Er: a potential step forward for its utilization in in vivo therapeutic applications.Evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers.Synthesis and Preclinical Evaluation of (177)Lu-CHX-A"-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma.(131)I-Nimotuzumab - A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR.Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.Development of a phantom and assessment of (141)Ce as a surrogate radionuclide for flood field uniformity testing of gamma cameras.Development of single vial kits for preparation of (68)Ga-labelled peptides for PET imaging of neuroendocrine tumours.
P50
Q33396092-A251CBC1-B046-40C5-9DE4-687F24D736D0Q33417511-EE24B613-1764-434A-ADBE-32B8E90C1377Q33990728-4152EED6-2F3C-414E-90D0-FFD5331D6C8CQ34272526-C307CC65-E859-48E6-9F39-B4ABFCE13A7FQ34542733-B23CF97C-89F4-4372-AFFE-B2FC2922B1C6Q35566919-6621A194-3C06-4946-BCF3-9CD0B2AAC1F7Q35724907-98F1F514-3B58-409D-BC6F-6131E3717A47Q36234605-30271896-DCF7-4E81-ACF2-9D524DBA0D23Q36769707-D65261F0-27B3-4E44-9E8B-80C7D687B244Q37733430-40C2C419-792A-4CD8-8B2E-D529BFD7E148Q38046260-D018AE0C-954D-49C5-AFB0-0477E95FE1DCQ38059036-100CE3D0-E2FB-4341-918C-003537E31BCDQ38114110-A8743624-BC7D-4A0B-AB98-B32F73DB9AB8Q38908785-80565781-E2A9-486D-8563-673FE4635B1CQ39042278-40F7924F-5550-448A-A8E8-9D54B33AF84DQ39500323-23550B68-EDA9-4326-8434-CCC2D770ACC5Q39982739-A5237413-45F7-4F9D-AED8-D610B049F4B5Q40364269-E675F743-05E0-4254-BD96-449CE22B68F2Q40616136-226C00E7-541E-4827-873E-B7EB385F352CQ41610069-8055C2E8-035A-437B-9EA1-B31866164A8DQ43178248-949E4AB9-E891-4D87-A8CE-366E2A5BDC43Q43740173-5FA3FF0A-B0F2-446A-9440-0F0F69212D7BQ44964768-68C749F1-C279-42B8-99AE-DE51896603A1Q46065160-A8D0BDE1-450B-4776-A71A-1F5EB31D6307Q46076542-9EA28371-5FA2-45E8-BB56-A6C3213611A2Q46219523-25B44FB2-1B95-48AA-8947-AA5F0251A111Q46565390-58F94556-E197-4291-8E33-835625CCE4C8Q46723776-530E5398-E19F-4BFB-A6D6-868C0FC61C8AQ50771746-36D0483F-0F9E-4FD9-80DB-C3697206FD17Q50802390-D5813C49-CFD4-4FBF-921A-44924E9FA2E7Q51022591-4B857420-7B47-4480-8894-49A42CC1190AQ51071902-E515C216-13BA-49D7-BA8B-9C19585FA4C4Q51539256-793A8832-07D9-4800-B7D9-2F7776556C11Q51755845-2893CD50-AF15-4906-AD55-F4C7DFD41D3AQ52865937-F7C854A0-C3C9-41D3-A83A-3B38DF64C86DQ52937382-4466500D-53AD-41F5-A7B1-7096E6C39741Q52941423-F67F7EE4-B003-435D-AF30-C28069189309Q52982515-3B0EB258-9A1E-4D1A-B313-DB90D98E5B92Q52983998-4A28249E-ABDC-4304-8D33-739008C4055FQ53081413-A9BF8CFA-EFEB-463E-B4BF-1E15526F3F4C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ashutosh Dash
@ast
Ashutosh Dash
@en
Ashutosh Dash
@es
Ashutosh Dash
@nl
type
label
Ashutosh Dash
@ast
Ashutosh Dash
@en
Ashutosh Dash
@es
Ashutosh Dash
@nl
prefLabel
Ashutosh Dash
@ast
Ashutosh Dash
@en
Ashutosh Dash
@es
Ashutosh Dash
@nl
P106
P1153
16038610600
P31
P496
0000-0001-7541-7298